Skip to content

R&D at other companies

Teledyne Technologies logo
Teledyne TechnologiesTDY
$84.6M+13.9%
Keysight Technologies logo
Keysight TechnologiesKEYS
$320M+28.0%
Element Solutions logo
Element SolutionsESI
$20.2M+27.0%
Semtech logo
SemtechSMTC
$57.57M+21.1%
Onto Innovation logo
Onto InnovationONTO
$35.1M+25.2%
Mettler-Toledo International, Inc. logo
Mettler-Toledo International, Inc.MTD
$51.28M+10.6%

Other financials

Income statement

See full
Revenue$534.6M+11.0%
Gross profit$272.3M+11.9%
Operating income$68.1M-7.7%
Net income$44.2M-30.8%
EPS (diluted)$0.39-31.6%

Balance sheet

See full
Cash & equivalents$268.0M
Total debt$1.2B
Total equity$1.6B-59.3%
Total assets$3.7B

Cash flow

See full
Operating cash flow$19.1M-73.5%
CapEx$8.7M+55.4%
Free cash flow$10.4M-84.3%

Valuation

See full
Market cap$7.63B
Enterprise value$8.59B
P/S3.6×

Profitability

See full
Gross margin50.4%-1.1pp
Operating margin-56%-74.8pp
Net margin-58.6%-73.0pp
FCF margin14.3%

Returns & leverage

See full
Return on equity-45.9%-53.6pp
Debt / equity0.8×
Current ratio1.6×

Where this comes from

Reported directly by RAL in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: RAL’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about RAL's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RAL's R&D?
RAL (RAL) reported R&D of $43.7M in Q1 2026.
How has RAL's R&D changed year-over-year?
RAL's R&D increased by 5.8% year-over-year, from $41.3M to $43.7M.
What is the long-term trend for RAL's R&D?
Over 2 years (2023 to 2025), RAL's R&D has grown at a 1.1% compound annual growth rate (CAGR), from $161.5M to $165M.
What does R&D mean?
Spending dedicated to creating new products or improving existing technology.
How do you interpret R&D?
Higher spending signals a commitment to innovation and future growth, though it may temporarily depress current earnings.
How does R&D compare across companies?
High R&D intensity is expected in technology and pharmaceutical sectors compared to traditional industrial firms.